• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Gastroenterology

Pembrolizumab linked to longer cancer-free period in advanced colon cancer

byRicha SharmaandDeepti Shroff, DMD, MS
January 24, 2021
in Gastroenterology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In a phase 3 trial across 23 countries, Pembrolizumab displayed a longer cancer-free period when compared to the first line therapy for metastatic microsatellite instability or mismatch-repair deficiency (MSI-H-dMMR) colorectal cancer.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A subset of colorectal cancer tumors is mismatch-repair deficiency (dMMR) which has been known to be the leading cause of colorectal cancer in 15% of those diagnosed. However, there is sufficient evidence that suggests that current first line chemotherapy does not produce the desired response. This study was conducted as a multicenter, open-label, randomized control trial that compared pembrolizumab with the recommended first line chemotherapy as suggested by the investigator for MSI-H-dMMR metastatic colorectal cancer. The follow up period for this study was 32.4 months where the patients were randomized into standard-of-care chemotherapy or pembrolizumab. This study also examined adverse effects, disease progression, mean survival, progression-free survival, overall survival, response rate, and efficacy among other things. Overall, pembrolizumab displayed a higher response rate when compared to traditional chemotherapy. Similar adverse events were noted in both groups.

This study was successful at randomizing a large sample size and collecting data over a long course.

Click to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

RELATED REPORTS

Obesity associated with higher early-onset cancer risk among young Korean adults

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

In-Depth [randomized controlled trial]: This open label, phase 3 trial was conducted across 23 countries where 307 patients were assigned randomly into one of two groups at 192 sites between February 2016 to February 2018. Patients were eligible if over 18 years of age, with radiologically confirmed and diagnosed MSI-H-dMMR stage IV colorectal cancer, with normal to adequate organ function. Patients were excluded from the study if they received previous adjuvant chemotherapy for this condition in the last six months. One group was given 200 mg of pembrolizumab intravenously every 3 weeks. The other group was given chemotherapy (mFOLFOX6, mFOLFOX6 plus bevacizumab, mFOLFOX6 plus cetuximab, FOLFIRI, FOLFIRI plus bevacizumab or FOLFIRI plus cetuximab) every 2 weeks based on the investigator’s choice of first line therapy for metastatic MSI-H-dMMR colorectal cancer. A maximum number of treatments was assigned to Group A, unless the patient wanted to withdraw from trial, or physician’s opinion was to withdraw the patient from the trial, or the patient developed serious side effects or illness during the course of treatment. Further assessments were conducted by using polymerase-chain-reaction-based analysis and imaging along with ongoing evaluation of side effects and/or adverse events. Overall, the power of the study was approximated at 98%, mean age of patients was 63, median time of treatment exposure was 11.1 months in pembrolizumab group and 5.7 months in the chemotherapy group. The study results indicate that the pembrolizumab group displayed longer progression-free survival when compared to the chemotherapy group with an overall response rate of 83% and 35%, respectively. The most common side effects of pembrolizumab were diarrhea, fatigue and nausea versus for the chemotherapy group, diarrhea, nausea and fatigue.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancercolorectal cancerPembrolizumab
Previous Post

Focused ultrasound subthalamotomy revealed improvement in Parkinson’s patients

Next Post

REGN-COV2 antibody cocktail may reduces viral load in Covid-19 patients

RelatedReports

Obesity measurement collage: a bathroom scale with a blank dial, a loose cloth measuring tape, an apple and a pear
Chronic Disease

Obesity associated with higher early-onset cancer risk among young Korean adults

November 13, 2026
A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
An illustration depicting the colon with IV bags on either side, symbolizing sequential therapy paths in colorectal cancer treatment.
Gastroenterology

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

October 29, 2026
An envelope is being held with a calendar and an illustration of the colon in the background, indicating a reminder for colorectal screening.
2MM Trial Briefs

WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer

October 26, 2026
Next Post
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

REGN-COV2 antibody cocktail may reduces viral load in Covid-19 patients

CD45 T cell and macrophage infiltration characteristic of COVID-19 related lung injury

2 Minute Medicine Rewind January 25, 2021

Schoolchildren aged 6-8 years experiencing increased prevalence of myopia following house confinement from COVID-19

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.